AboutContact us
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Oracle’s stock has fallen 40% since Safra Catz announced her exit. Its latest earnings didn’t calm investors.
2
Freed Nvidia engineer Avinatan Or meets Jensen Huang at U.S. headquarters
3
After over $390 million in funding, Believer Meats abruptly shuts down
4
Jensen Huang’s quiet role emerges as Argamani describes Nvidia’s two-year vigil for Avinatan Or
5
Israel’s quantum boom: Startups hit $500 million in funding in 2025
More news

Compugen

5 stories about Compugen
מנכ"לית קומפיוג'ן ד"ר ענת כהן דייג

Compugen shares soar on massive deal with Gilead, worth up to $848 million

19.12.23|Sophie Shulman
The Israeli company utilizes its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing novel cancer immunotherapies
נאסדק

Compugen Falls 17% on Employee Cuts Announcement

27.02.19|Lilach Baumer
The Nasdaq-listed cancer immunotherapy company published its fourth quarter and full year results for 2018 Tuesday
ענת כהן-דייג מנכ"לית קומפיוג'ן

Bristol-Myers Squibb Invests $12 Million in Israeli Immunotherapy Company Compugen

12.10.18|Dror Reich
The investment is part of a clinical trial collaboration for a treatment that combines Compugen’s investigational antibody with an immune checkpoint inhibitor from Bristol-Myers Squibb
נאסדק נאסד"ק ניו יורק בורסה בועה

Biotech Company Compugen Down on Nasdaq Following $21 Million Direct Offering

17.06.18|Dror Reich
The Israel-based cancer immunotherapy company intends to use the proceedings for product development
ענת כהן-דייג מנכ"לית קומפיוג'ן

AstraZeneca Signs Deal with Cancer Immunotherapy Company Compugen

03.04.18|Lilach Baumer
The deal has the potential to be worth over $200 million for Nasdaq-listed Compugen